The FABP2 gene polymorphism in cerebrovascular disease
P Wanby1, P Palmquist, I Rydén
1Department of Internal Medicine, County Hospital of Kalmar, Kalmar, Sweden.
Acta Neurologica Scandinavica
|November 6, 2004
Summary
The fatty acid binding protein 2 (FABP2) A54T gene variant may increase the risk of cerebrovascular disease (CVD), particularly for transient ischemic attacks (TIAs) and non-cardioembolic infarction in younger individuals.
Area of Science:
- Genetics
- Neurology
- Cardiovascular Science
Background:
- The fatty acid binding protein 2 (FABP2) T54 allele is linked to dyslipidemia, a risk factor for cerebrovascular disease (CVD).
- Genetic variations in FABP2 may influence CVD susceptibility.
Purpose of the Study:
- To investigate the association between the FABP2 gene A54T polymorphism and the risk of developing CVD.
- To determine if specific FABP2 genotypes are risk factors for different types of cerebrovascular events.
Main Methods:
- A case-control study was conducted with 407 acute CVD patients and 158 controls.
- Genotyping for the FABP2 A54T polymorphism was performed using the PCR-RFLP method.
Main Results:
- Overall allele and genotype frequencies of FABP2 A54T did not significantly differ between CVD patients and controls.
- A higher combined frequency of TT and TA genotypes was observed in patients with transient ischemic attacks (TIAs) compared to controls (P=0.05).
- The TT genotype was more prevalent in non-smoking patients under 70 with non-cardioembolic infarction versus controls (P=0.024).
Conclusions:
- The FABP2 A54T gene polymorphism may play a role in the pathogenesis of CVD.
- The FABP2 T54 allele is suggested as a genetic susceptibility marker for TIA and early-onset non-cardioembolic infarction.
Related Concept Videos
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...